Y. Qian et al., IDENTIFICATION AND CHARACTERIZATION OF ANTIDEPRESSANT-SENSITIVE SEROTONIN TRANSPORTER PROTEINS USING SITE-SPECIFIC ANTIBODIES, The Journal of neuroscience, 15(2), 1995, pp. 1261-1274
Serotonin (5HT) transporters (SERTs) are responsible for clearance of
synaptic and plasma 5HT and are molecular targets for multiple therape
utic and addictive compounds. Recently brain and peripheral SERT cDNAs
have been cloned and characterized functionally in transfected cells.
Antipeptide (S365) and anti-fusion protein (CT-2) antibodies, directe
d at epitopes poorly conserved among other Na+/Cl- cotransporters, hav
e been prepared to facilitate the identification and characterization
of SERT proteins in native and transfected cells. Immunoprecipitations
and immunoblots of rat/human SERT-transfected HeLa cells reveal speci
fic SERT-immunoreactive glycoproteins absent from extracts of vector-t
ransfected cells and absent when incubations were conducted using pept
ide- or fusion protein-absorbed antibody. In SDS-PAGE of membranes pre
pared from rat midbrain and cortex, SERTs migrate as single 76 kDa pol
ypeptides with a relative abundance consistent with the known distribu
tion of 5HT neurons and axonal projections. SERT-immunoreactive protei
ns are also detectable in platelet and pulmonary membranes, sites of p
eripheral 5HT uptake, but not in liver. Our studies also indicate that
brain and platelet SERTs are formed from identical polypeptides diffe
ring significantly in their extent of N-linked glycosylation. Immunocy
tochemistry performed on rat brain sections with CT-2 antibody reveale
d SERT expression associated with brainstem raphe nuclei in a pattern
virtually identical to that obtained by labeling adjacent sections wit
h 5HT antisera. SERT-immunoreactive fibers were found to be widely dis
tributed throughout the rodent brain, with highest density in forebrai
n regions known to receive a dense serotonergic innervation. in a simi
lar manner, CT-2 antibody also detects endogenous expression of human
SERT proteins, providing an opportunity for future studies on the modu
lation of transporter protein expression in neurologic and psychiatric
disorders.